Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Safety and Efficacy of Zoledronic Acid in Children with Osteogenesis Imperfecta

View through CrossRef
Objective: To evaluate the safety and efficacy of zoledronic acid in peditarian cases of osteogenesisimperfecta in terms of improving the clinical severity score.Material and Methods: This case series was conducted using non-probability consecutive samplingtechnique. We enrolled 83 cases of osteogenesis imperfecta diagnosed on history, clinical examination andradiographs. All children were classified according to Sillence classification for Osteogenesis Imperfectarespectively (type I, II, III and IV). The clinical severity score was measured, and all children were classifiedin mild, moderate and severe type based on clinical findings. All children who were already taking anymedical treatment were excluded from the study. After adequate hydration, all children received anintravenous infusion of zoledronic acid 0.1mg/kg/BW diluted in 100ml normal saline over one hour on daycare basis. All children were monitored for adverse effects: pyrexia, arthralgia myalgia and headachesymptoms. Three doses of zoledronic acid were given at 1st day, six month and 1 year. The clinical severityscore was measured after two year of the initial doseResults: Out of the total 83 children, the male to female ratio was 4:1. There were Sillence type I, II & IV wasfound in 24 (28.9%), 30 (36.1%) and 29 (34.9%) children respectively. The mean age of the children was7.2±2.45year. The mean difference of clinical severity score before and after the treatment was 11.88±2.65and 10.08±3.40 respectively (p-value <0.001). The mean value of average number of fractures before andafter treatment was 4.32±1.83 and 0.94±0.78 respectively (p-value<0.001). The mean difference in BMDbefore and after treatment was -4.82±1.54 and -2.10±0.83 respectively (p-value<0.001). The annualimprovement in fracture incidence was 82±6.55 and the annual BMD improvement was 54.33±7.09 till lastfollow-up.Conclusion: Zoledronic acid was a safe and effective drug in treating children with Osteogenesis Imperfecta.It improved the bone mineral density as well as reduced the average number of fractures per year, thusimproving the clinical severity score.Keyword: osteogenesis imperfecta, zoledronic acid, clinical severity score, sillence classification, bonemineral density, bisphosphonates.How to cite: Cheema OI, Muhibi AS, Javed MT, Akhtar M, Shafiq Z, Nadeem RD. Safety and Efficacy of ZoledronicAcid in Children with Osteogenesis Imperfecta. Esculapio - JSIMS 2026;22(03):DOI: 10.51273/esculap.v22i03.1652
Title: Safety and Efficacy of Zoledronic Acid in Children with Osteogenesis Imperfecta
Description:
Objective: To evaluate the safety and efficacy of zoledronic acid in peditarian cases of osteogenesisimperfecta in terms of improving the clinical severity score.
Material and Methods: This case series was conducted using non-probability consecutive samplingtechnique.
We enrolled 83 cases of osteogenesis imperfecta diagnosed on history, clinical examination andradiographs.
All children were classified according to Sillence classification for Osteogenesis Imperfectarespectively (type I, II, III and IV).
The clinical severity score was measured, and all children were classifiedin mild, moderate and severe type based on clinical findings.
All children who were already taking anymedical treatment were excluded from the study.
After adequate hydration, all children received anintravenous infusion of zoledronic acid 0.
1mg/kg/BW diluted in 100ml normal saline over one hour on daycare basis.
All children were monitored for adverse effects: pyrexia, arthralgia myalgia and headachesymptoms.
Three doses of zoledronic acid were given at 1st day, six month and 1 year.
The clinical severityscore was measured after two year of the initial doseResults: Out of the total 83 children, the male to female ratio was 4:1.
There were Sillence type I, II & IV wasfound in 24 (28.
9%), 30 (36.
1%) and 29 (34.
9%) children respectively.
The mean age of the children was7.
2±2.
45year.
The mean difference of clinical severity score before and after the treatment was 11.
88±2.
65and 10.
08±3.
40 respectively (p-value <0.
001).
The mean value of average number of fractures before andafter treatment was 4.
32±1.
83 and 0.
94±0.
78 respectively (p-value<0.
001).
The mean difference in BMDbefore and after treatment was -4.
82±1.
54 and -2.
10±0.
83 respectively (p-value<0.
001).
The annualimprovement in fracture incidence was 82±6.
55 and the annual BMD improvement was 54.
33±7.
09 till lastfollow-up.
Conclusion: Zoledronic acid was a safe and effective drug in treating children with Osteogenesis Imperfecta.
It improved the bone mineral density as well as reduced the average number of fractures per year, thusimproving the clinical severity score.
Keyword: osteogenesis imperfecta, zoledronic acid, clinical severity score, sillence classification, bonemineral density, bisphosphonates.
How to cite: Cheema OI, Muhibi AS, Javed MT, Akhtar M, Shafiq Z, Nadeem RD.
Safety and Efficacy of ZoledronicAcid in Children with Osteogenesis Imperfecta.
Esculapio - JSIMS 2026;22(03):DOI: 10.
51273/esculap.
v22i03.
1652.

Related Results

Zoledronic Acid Is Not Equally Potent on Osteoclasts Generated From Different Individuals
Zoledronic Acid Is Not Equally Potent on Osteoclasts Generated From Different Individuals
ABSTRACT Zoledronic acid is a bisphosphonate commonly used to treat bone diseases such as osteoporosis and cancer‐induced bone disease. Patie...
HRQoL Evaluation of Pediatric Osteogenesis Imperfecta with Zoledronic Acid Therapy
HRQoL Evaluation of Pediatric Osteogenesis Imperfecta with Zoledronic Acid Therapy
Background: Zoledronic acid as bisphosphonates could increase bone mineral density (BMD), which in osteogenesis imperfecta will reduce clinical manifestations. Pediatric patients w...
How zoledronic acid improves osteoporosis by acting on osteoclasts
How zoledronic acid improves osteoporosis by acting on osteoclasts
Osteoporosis is called a silent disease, because it is difficult to detect until comprehensive examinations for osteoporosis are performed or osteoporotic fractures occur. Zoledron...
Effects of zoledronic acid combined with metformin on bones of DB/DB mice
Effects of zoledronic acid combined with metformin on bones of DB/DB mice
Abstract Background Diabetic patients are prone to osteoporosis. Both zoledronic acid and metformin have certain anti-osteoporotic effects.Here we explore the anti-osteopo...
Local Administration of Zoledronic Acid for Giant Cell Tumor of Bone
Local Administration of Zoledronic Acid for Giant Cell Tumor of Bone
Giant cell tumor of bone is a locally aggressive tumor with a high local recurrence rate. Several adjuvant therapies have been employed to reduce the recurrence rate, but their eff...
The Burden of Road Traffic Injuries: A Global Perspective
The Burden of Road Traffic Injuries: A Global Perspective
Introduction     Road Traffic Injury (RTI) pose a significant health challenge. It represents the eighth leading cause of death globally, prompting the UN to designate 2011-2020 as...
An Algorithm for Managing Syndromic Craniosynostosis Using Posterior Vault Distraction Osteogenesis
An Algorithm for Managing Syndromic Craniosynostosis Using Posterior Vault Distraction Osteogenesis
Background: The authors hypothesize that early posterior vault distraction osteogenesis safely confers considerable cranial vault remodeling, sufficient to enable front...
Osteogenesis Imperfecta
Osteogenesis Imperfecta
AbstractOsteogenesis imperfecta is an autosomal dominant disorder of connective tissue, commonly known as “brittle bone disease.” The frequency of osteogenesis imperfecta identifia...

Back to Top